

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

^{Pr}**AG-Olopatadine 0.2%**

Olopatadine Hydrochloride Ophthalmic Solution

Ophthalmic Solution, 0.2% w / v olopatadine (as olopatadine hydrochloride), topical

USP

Anti-allergy Agent

ATC code: S01GX09

Angita Pharma Inc.
1310 rue Nobel
Boucherville, Québec
J4B 5H3, Canada

Date of Initial
Authorization: JAN 16, 2026

Submission Control Number: 301865

RECENT MAJOR LABEL CHANGES

None at the time of authorization.

TABLE OF CONTENTS

Certain sections or subsections that are not applicable at the time of preparation of the most recent authorized product monograph are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics.....	4
1.2 Geriatrics.....	4
2 CONTRAINDICATIONS	4
4 DOSAGE AND ADMINISTRATION	4
4.1 Dosing Considerations	4
4.2 Recommended Dose and Dosage Adjustment	4
4.5 Missed Dose	4
5 OVERDOSAGE	4
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	5
7 WARNINGS AND PRECAUTIONS	6
7.1 Special Populations	6
7.1.1 Pregnant Women	6
7.1.2 Breast-feeding	7
7.1.3 Pediatrics.....	7
7.1.4 Geriatrics:.....	7
8 ADVERSE REACTIONS	7
8.1 Adverse Reaction Overview	7
8.2 Clinical Trial Adverse Reactions	7
8.3 Less Common Clinical Trial Adverse Reactions.....	7
8.5 Post-Market Adverse Reactions	8
9 DRUG INTERACTIONS	8
9.2 Drug Interactions Overview	8
10 CLINICAL PHARMACOLOGY	9
10.1 Mechanism of Action	9
10.2 Pharmacodynamics	9
10.3 Pharmacokinetics	9
11 STORAGE, STABILITY AND DISPOSAL	11
PART II: SCIENTIFIC INFORMATION	12
13 PHARMACEUTICAL INFORMATION	12

14	CLINICAL TRIALS	13
	14.1 Clinical Trials by Indication	13
16	NON-CLINICAL TOXICOLOGY.....	17
17	SUPPORTING PRODUCT MONOGRAPHS	18
	PATIENT MEDICATION INFORMATION.....	19

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

AG-Olopatadine 0.2% (olopatadine hydrochloride ophthalmic solution) is indicated for:

- the treatment of ocular itching associated with seasonal allergic conjunctivitis.

1.1 Pediatrics

Pediatrics (<18 years): The effectiveness of olopatadine hydrochloride ophthalmic solution has not been established in pediatric patients <18 years of age. No overall difference in safety has been observed between pediatric and adult patients.

1.2 Geriatrics

Geriatrics: No overall differences in safety and effectiveness have been observed between elderly and other adult patients.

2 CONTRAINDICATIONS

Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see 6 [DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#) section of the Product Monograph.

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

No special dosage considerations are necessary for AG-Olopatadine 0.2%.

4.2 Recommended Dose and Dosage Adjustment

The recommended dose is one drop in each affected eye once a day.
No dosage adjustment is required in hepatic or renal impairment.

4.5 Missed Dose

If a dose is missed, a single drop should be taken as soon as possible before reverting to regular routine. Do not use a double dose to make up for the one missed.

5 OVERDOSAGE

No data are available in humans regarding overdose by accidental or deliberate ingestion of olopatadine hydrochloride ophthalmic solution. No reports of overdose were received during

the clinical studies of olopatadine hydrochloride ophthalmic solution.

If a topical overdose of AG-Olopatadine 0.2% occurs, the eye(s) may be flushed with tap water.

For the most recent information in the management of suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1: Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength / Composition	Non-medicinal Ingredients
Topical Ophthalmic	Ophthalmic Solution / 0.2% w / v olopatadine (as olopatadine hydrochloride)	Preservative: Benzalkonium chloride Non-medicinal ingredients: Dibasic sodium phosphate, edetate disodium, hydrochloric acid and / or sodium hydroxide (to adjust pH), povidone, sodium chloride, water for injection.

Description

Each mL of AG-Olopatadine 0.2% contains:

Medicinal ingredient: 2.22 mg olopatadine hydrochloride equivalent to 2 mg olopatadine.

Preservative: Benzalkonium chloride 0.01%.

Non-medicinal ingredients: See Table 1 for complete list.

AG-Olopatadine 0.2% has a pH of approximately 5.0 to 8.0 and an osmolality of approximately 260 to 340 mOsm / kg.

AG-Olopatadine 0.2% is supplied in a white, low density polyethylene bottle with natural LDPE nozzle and white HDPE screw-on cap.

Net contents are 2.5 mL in a 5 mL bottle.

7 WARNINGS AND PRECAUTIONS

General

For topical ocular use only. Not for injection or oral use.

Contamination

As with any eye drop, to prevent contamination of the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.

Driving and Operating Machinery

Olopatadine is a non-sedating anti-histamine. Temporary blurred vision or other visual disturbances, after the use of AG-Olopatadine 0.2%, may affect the ability to drive or use machines. If blurred vision occurs after instillation, patients must wait until vision clears before driving or using machinery.

Ophthalmologic

Patients should be advised not to wear contact lenses if their eye(s) are red.

AG-Olopatadine 0.2% should not be used to treat contact lens related irritation. The preservative in AG-Olopatadine 0.2%, benzalkonium chloride, may cause eye irritation and is known to discolour soft contact lenses. Contact with soft contact lenses should be avoided. Patients must be instructed to remove contact lenses prior to application of AG-Olopatadine 0.2%, and wait at least 15 minutes before they insert their contact lenses.

If using other eye drops, patients should wait at least five minutes between putting in AG-Olopatadine 0.2% and the other drops. Eye ointments should be applied last.

Reproductive Health: Female and Male Potential

- **Fertility**

Studies have not been performed to evaluate the effect of topical ocular administration of olopatadine on human fertility.

7.1 Special Populations

7.1.1 Pregnant Women

There are no adequate and well controlled studies in pregnant women. Studies in animals with olopatadine have shown reproductive toxicity following systemic administration considered sufficiently in excess of the maximum human exposure. Olopatadine was found not to be teratogenic in rats and rabbits at oral doses >90,000 and >60,000 times the maximum recommended ocular human use level, respectively (see [16 NON-CLINICAL](#))

[TOXICOLOGY, Reproductive and developmental Toxicology](#)). Because animal studies are not always predictive of human responses, AG-Olopatadine 0.2% should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

7.1.2 Breast-feeding

Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in human breast milk. Nevertheless, caution should be exercised when AG-Olopatadine 0.2% is administered to a nursing mother.

7.1.3 Pediatrics

Pediatrics (<18 years): Effectiveness in pediatric patients has not been established. No overall difference in safety has been observed between pediatric and adult patients.

7.1.4 Geriatrics:

No overall differences in safety and effectiveness have been observed between elderly and other adult patients.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

In clinical trials involving 1137 patients dosed with long-term ophthalmic topical therapy, olopatadine hydrochloride ophthalmic solution was administered once-daily for 4 to 12 weeks. The most frequently reported treatment-related undesirable effects were headache (0.8%), eye irritation (0.5%), dry eye (0.4%), and eyelid margin crusting (0.4%). No serious adverse drug reactions related to olopatadine hydrochloride ophthalmic solution were reported in the clinical trials.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

No treatment-related adverse drug reactions occurred at an incidence \geq 1%.

8.3 Less Common Clinical Trial Adverse Reactions

The most frequently reported adverse drug reactions (>0.1%) are presented below.

Treatment-Related Adverse Drug Reactions >0.1% – Long-Term Exposure

Eye disorders: eye irritation, dry eye, eyelid margin crusting, and eye pruritus;

Gastrointestinal disorders: dry mouth;

Nervous system disorders: headache, dysgeusia;

Additional treatment-related adverse drug reactions that occurred at an incidence of 0.1% included the following:

Eye disorders: asthenopia, eye swelling, eyelid disorder, eyelids pruritus, ocular hyperaemia, and vision blurred;

Investigations: heart rate increased;

Respiratory, Thoracic, and Mediastinal disorders: nasal dryness;

8.5 Post-Market Adverse Reactions

Approximately 5.4 million units of olopatadine hydrochloride ophthalmic solution have been sold worldwide. The reporting rate of all reaction terms reported between 22 December 2004 and 31 August 2009 was 0.005%, and no single reaction term occurred with a reporting rate greater than 0.0007%. No post-market reports of serious adverse reactions have been received to date. The most frequent events reported being eye irritation, ocular hyperaemia, eye pain, and vision blurred. There were no new major findings bearing on the established overall safety profile of olopatadine hydrochloride ophthalmic solution. Other events include dizziness, eye discharge, punctate keratitis, keratitis, erythema of eyelid, dermatitis contact, fatigue, hypersensitivity, ocular discomfort, lacrimation increased and nausea.

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

No clinical interaction studies have been conducted with olopatadine hydrochloride ophthalmic solution. *In vitro* studies have shown that olopatadine does not inhibit metabolic reactions which involve cytochrome P-450 isoenzymes 1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4. Olopatadine is moderately bound to plasma proteins (approximately 55%). These results indicate that olopatadine is unlikely to result in interactions with other concomitantly administered medications. Due to the low systemic exposure following topical ocular dosing, it is unlikely that AG-Olopatadine 0.2% would interfere with immediate hypersensitivity skin testing.

Interactions with other drugs, food, herbal products, or laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Olopatadine, a structural analog of doxepin, is a non-steroidal, non-sedating, topically effective anti-allergic molecule that exerts its effects through multiple distinct mechanisms of action. Olopatadine is a mast cell stabilizer and a potent, selective histamine H₁ antagonist that inhibits the *in vivo* type 1 immediate hypersensitivity reaction. *In vitro* studies have demonstrated the ability of olopatadine to stabilize rodent basophils and human conjunctival mast cells and inhibit immunologically-stimulated release of histamine. In addition, Olopatadine inhibits the release of mast cell inflammatory mediators [i.e., histamine, tryptase, prostaglandin D₂ and TNF α] as demonstrated in *in vitro* studies and confirmed in patients.

Olopatadine is a selective histamine H₁ receptor antagonist *in vitro* and *in vivo* as demonstrated by its ability to inhibit histamine binding and histamine-stimulated vascular permeability in the conjunctiva following topical ocular administration. Olopatadine is also an inhibitor of pro-inflammatory cytokine secretion from human conjunctival epithelial cells. Decreased chemotaxis and inhibition of eosinophil activation has also been reported. Olopatadine is devoid of effects on alpha-adrenergic, dopamine, muscarinic type 1 and 2, and serotonin receptors.

10.2 Pharmacodynamics

Effects on cardiac repolarization (QTc):

Olopatadine had no observed effect on heart rate, cardiac conduction (PR and QRS interval duration), cardiac repolarization (QT duration) or wave form morphology relative to placebo in 2 double-masked, placebo controlled, 2-way crossover studies of 102 subjects given 5-mg oral doses of olopatadine every 12 hours for 2.5 days and 32 subjects given 20-mg oral doses twice-daily for 13.5 days. No clinically relevant or statistically significant changes in mean QTcF (determined to be the most appropriate heart correction formula for both study populations) at steady-state from baseline were observed in either study. A categorical analysis of QTc (< 30 ms, 30 ms-60 ms, or > 60 ms) showed no statistically significant differences between olopatadine and placebo in both studies. An analysis of the maximal change from baseline in QTcF showed the difference was higher for placebo than for olopatadine. In addition, no evidence of QT interval prolongation was observed, relative to placebo, in 429 perennial allergic rhinitis patients given olopatadine hydrochloride nasal spray, 665 micrograms twice daily for up to 1 year.

10.3 Pharmacokinetics

Systemic bioavailability data upon topical ocular administration of olopatadine hydrochloride ophthalmic solution are not available.

Absorption:

Following topical ocular administration in man, olopatadine was shown to have low systemic exposure. Two studies in healthy volunteers (totaling 24 subjects) dosed bilaterally with Olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (<0.5 ng/mL). Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. These plasma concentrations were greater than 300 fold below those observed with a well-tolerated 20 mg oral multiple-dose regimen. In oral studies, olopatadine was found to be well absorbed.

In multiple oral dose studies, olopatadine plasma concentrations were shown to increase in proportion to the dose increment.

Metabolism:

Approximately 60-70% of the oral dose was recovered in the urine as parent drug. Peak plasma concentrations of the active metabolite, N-desmethyl olopatadine, and inactive N-oxide metabolite were low, less than 1% and 3% of parent, respectively. Two metabolites, the monodesmethyl and the N-oxide, were detected at low concentrations in the urine.

Elimination: The elimination half-life in plasma was 7-14 hours, and elimination was predominantly through renal excretion.

Special Populations and Conditions

- **Pediatrics** - Effectiveness in pediatric patients has not been established. No overall difference in safety has been observed between pediatric and adult patients.
- **Geriatrics** - No overall differences in safety and effectiveness have been observed between elderly and other adult patients.
- **Sex** - In multiple oral dose studies, plasma concentrations of olopatadine are higher in female subjects, however, the differences are small and not clinically meaningful.
- **Ethnic Origin** - No specific pharmacokinetic study examining the effect of race has been conducted.
- **Hepatic Insufficiency** - No specific pharmacokinetic study examining the effect of hepatic impairment was conducted. Since metabolism of olopatadine is a minor route of elimination, no adjustment of the dosing regimen of AG-Olopatadine 0.2% is warranted in patients with hepatic impairment
- **Renal Insufficiency** - The mean plasma C_{max} values for olopatadine following single intranasal doses of olopatadine hydrochloride nasal spray 0.6% (665 mcg/spray) were not markedly different between healthy subjects (18.1 ng/mL) and patients with mild,

moderate and severe renal impairment (range 15.5 to 21.6 ng/mL). Plasma AUC was 2.5-fold higher in patients with severe impairment (creatinine clearance <30 mL/min/1.73m²). Predicted peak steady-state plasma concentrations of olopatadine in patients with renal impairment following administration of olopatadine hydrochloride ophthalmic solution, 0.1% are at least 10-fold lower than those observed following administration of olopatadine nasal spray 0.6%, and approximately 300-fold lower than those observed following the safe and well-tolerated administration of 20 mg oral doses for 13.5 days. These findings indicate that no adjustment of the dosing regimen of AG-Olopatadine 0.2% is warranted in patients with renal impairment.


11 STORAGE, STABILITY AND DISPOSAL

- Store between 4-25°C. Discard the bottle at the end of treatment or 4 weeks after first opening, whichever comes first. Do not use if seal is damaged or missing.
- Keep out of reach and sight of children.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name:	Olopatadine hydrochloride
Chemical name:	Dibenz[b,e]oxepin-2-acetic acid, 11-[3-(dimethylamino)propylidene]-6, 11-dihydro-,hydrochloride, (Z) 11-[(Z)-3-(Dimethylamino)propylidene]-6,11 dihydrodibenz[b,e]oxepin-2-acetic acid, hydrochloride
Molecular formula:	C ₂₁ H ₂₃ NO ₃ • HCl
Molecular mass:	373.87 g/mol
Structural formula:	
Description:	An off-white to white crystalline powder.
Solubility:	Very soluble in formic acid, sparingly soluble in water and very slightly soluble in dehydrated alcohol.
pH (1% aqueous solution):	Between 2.0 and 4.0

14 CLINICAL TRIALS

14.1 Clinical Trials by Indication

Ocular itching associated with seasonal allergic conjunctivitis

A summary of the patient demographics for each of the 7 studies relevant to the evaluation of the efficacy of olopatadine hydrochloride ophthalmic solution is provided in Table 2. Overall, these demographics are representative of the population that would be expected to receive this medicinal product.

Table 2 - Summary of patient demographics for clinical trials

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
C-00-36 CAC	randomized, double-masked, placebo-controlled	Olopatadine hydrochloride ophthalmic solution or placebo, 1 drop each eye at each visit, dosed contra-laterally; visits on 3 non- consecutive days	n = 45	42.3 yrs (19 – 70)	18 M 27 F
C-01-18 CAC	randomized, double-masked, placebo-controlled	Olopatadine hydrochloride ophthalmic solution, placebo, or Olopatadine hydrochloride ophthalmic solution and placebo dosed contra-laterally, 1 drop each eye at each visit, visits on 2 non-consecutive days	n = 36	38.1 yrs (20-58)	16 M 20 F
C-01-100 CAC	randomized, double-masked, placebo-controlled	Olopatadine hydrochloride ophthalmic solution (OU), placebo (OU), Olopatadine hydrochloride ophthalmic solution (OS) and placebo (OD), or Olopatadine hydrochloride ophthalmic solution (OD) and placebo (OS), 1 drop each eye at each visit, visits on 2 nonconsecutive days	n = 92	39.2 yrs (20-67)	38 M 54 F
C-02-67 Environmental (grass)	randomized, double-masked, placebo-controlled parallel group	Olopatadine hydrochloride ophthalmic solution or placebo, 1 drop each eye once daily, 10 weeks	n = 260	36.4 yrs (11-75)	123 M 137 F

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
C-04-60 Environmental (grass)	randomized, double-masked, placebo-controlled parallel group	Olopatadine hydrochloride ophthalmic solution or placebo, 1 drop each eye once daily, 6 weeks	n = 287	36.4 yrs (10-81)	127 M 160 F
C-01-10 Environmental (ragweed)	randomized, double-masked, placebo-controlled, parallel group	olopatadine hydrochloride ophthalmic solution or placebo, 1 drop each eye once daily, 12 weeks	n = 240	37.3 (10-66)	94 M 146 F
C-01-90 Environmental (grass)	randomized, double-masked, placebo-controlled, parallel group	olopatadine hydrochloride ophthalmic solution or placebo, 1 drop each eye once daily, 12 weeks	n = 239	37.4 (10-73)	94 M 145 F

OU= both eyes, OD=right eye, OS=left eye

Conjunctival Allergen Challenge (CAC) Studies:

Three studies were conducted to assess the safety and efficacy of olopatadine hydrochloride ophthalmic solution versus placebo in the treatment of allergen-mediated conjunctivitis using the CAC model at 27 minutes (onset-of-action), and either 16 hours or 24 hours or both (duration-of-action), after instillation. All three studies demonstrated that olopatadine hydrochloride ophthalmic solution dosed once daily was statistically superior to placebo in the treatment of ocular itching, has a rapid onset-of-action and a prolonged duration-of-action.

Table 3: CAC Itching Results from Contralateral Eye Analyses in Studies with olopatadine hydrochloride ophthalmic solution

		Onset-of-Action					24Hr Duration-of-Action					16Hr Duration-of-Action				
		time post-challenge					time post-challenge					time post-challenge				
		3 min	5 min	7 min	10 min	20 min	3 min	5 min	7 min	10 min	20 min	3 min	5 min	7 min	10 min	20 min
C-00-36 Olopatadine hydrochloride ophthalmic solution -Placebo	Mean Diff	-1.31			-1.60	-1.13	-0.93			-0.99	-0.65	-0.93			-0.88	-0.39
	P value	<0.001			<0.001	<0.001	<0.001			<0.001	<0.001	<0.001			<0.001	0.014
C-01-18 Olopatadine hydrochloride ophthalmic solution -Placebo	Mean Diff	-1.50			-1.67	-0.79						-1.25			-1.04	-0.50
	P value	0.0002			0.0003	0.0180						0.0011			0.0044	0.0456
C-01-100 Olopatadine hydrochloride ophthalmic solution -Placebo	Mean Diff	-1.56	-1.66	-1.53								-0.98	-1.07	-1.07		
	P value	<0.0001	<0.0001	<0.0001								<0.0001	<0.0001	<0.0001		

AG-Olopatadine 0.2%

(Olopatadine hydrochloride ophthalmic solution) Product Monograph

Shaded areas indicate that ocular itching was not evaluated at these time-points; bold numbers indicate statistical significance.


Environmental Studies:

Four environmental studies were designed to assess the safety and efficacy of olopatadine hydrochloride ophthalmic solution in comparison with placebo in the treatment of the signs and symptoms of seasonal allergic conjunctivitis. All studies were randomized, double-masked, placebo-controlled, multi-centre, parallel group studies. Three studies (C-02-67, C-04-60, and C-01-90) enrolled patients with a history of seasonal allergic conjunctivitis, a positive diagnostic skin prick test for grass antigen within the past 2 years, and a positive response to grass in the Conjunctival Allergen Challenge model of the required magnitude. One study (C-01-10) enrolled patients with a positive skin prick test for ragweed antigen. Daily pollen counts were recorded for each study site.

Clinical Study C-02-67

Two hundred and sixty (260) patients were enrolled in this 10-week environmental study. The primary efficacy analysis was based on the subject self-evaluation of the frequency of ocular itching during the three days prior to each weekly assessment visit. The results showed that olopatadine hydrochloride ophthalmic solution statistically significantly reduced the effects of pollen on ocular itching relative to vehicle when dosed once a day (Figure 1).

Figure 1: Mean Scores for Itching Frequency by Visit Day (Intent-to-Treat) (C-02-67)



An analysis of the slopes of the lines measuring the effects of pollen on ocular itching also showed a statistically significant difference between olopatadine hydrochloride ophthalmic solution and placebo when pollen counts were taken into consideration.

The secondary analysis showed that olopatadine hydrochloride ophthalmic solution, dosed once a day, statistically significantly reduced the effects of pollen on daily itching severity when compared to vehicle (Table 4).

Table 4: Mean Itching Severity during 14 Consecutive Days of Peak Pollen (Intent-to-Treat) (C-02-67)

		ITCHING
Olopatadine Hydrochloride Ophthalmic Solution	Mean	1.10
	Std	0.92
	N	127
PLACEBO	Mean	1.48
	Std	1.04
	N	129
Difference from Vehicle		-0.38
p-value (t-test)		0.0023

Clinical Study C-04-60

Two hundred and eighty-seven (287) patients were enrolled in this 6-week environmental study. Severity scores for daily ocular itching, as recorded by patients three times per day in their diaries, were statistically significantly lower compared to placebo in the morning, mid-day, and evening when *averaged over* the 14 consecutive days of the peak pollen period. Additionally, the average diary itching scores are statistically significantly reduced in patients treated with olopatadine hydrochloride ophthalmic solution compared with placebo (Table 5).

Table 5: Average Diary Itching Over the Peak Pollen Period by Time (Intent-to-Treat) (C-04-60)

Average Diary Itching					
		Mean	Std	N	P-value
Morning	Olopatadine Hydrochloride Ophthalmic Solution	0.55	0.60	144	0.0204
	Vehicle	0.72	0.64	143	
Mid-Day	Olopatadine Hydrochloride Ophthalmic Solution	0.50	0.61	144	0.0130
	Vehicle	0.69	0.63	143	
Evening	Olopatadine Hydrochloride Ophthalmic Solution	0.54	0.65	144	0.0084
	Vehicle	0.74	0.67	143	

Clinical Study C-01-10

A total of 240 patients were enrolled in this 12-week environmental study during ragweed season. The primary efficacy endpoint was subject self-evaluation of the frequency scores of ocular itching over a 12-week study period. The primary efficacy endpoint did not show any statistically significant difference between olopatadine hydrochloride ophthalmic solution and placebo in this study.

Clinical Study C-01-90

A total of 239 patients were enrolled in a 12-week environmental study during grass season. The primary efficacy endpoint was subject self-evaluation of the worst daily ocular itching averaged over a two-week, peak pollen period. The primary efficacy endpoint did not show any statistically significant difference between olopatadine hydrochloride ophthalmic solution and placebo in this study. The planned secondary efficacy analysis showed that olopatadine hydrochloride ophthalmic solution statistically significantly reduced the effects of pollen on ocular itching.

16 NON-CLINICAL TOXICOLOGY

General Toxicology:

The acute toxicity of olopatadine hydrochloride has been investigated in mice, rats and dogs. Mice and rats demonstrated that olopatadine hydrochloride was not an acute toxicity hazard with oral LD₅₀ values greater than 1150 mg/kg and 3870 mg/kg for mice and rats, respectively.

Subchronic and chronic oral toxicity studies in rats and dogs demonstrated that the liver and kidney were target organs for olopatadine hydrochloride toxicity. In rats, ophthalmology and hematology parameters were unaffected following chronic administration of olopatadine hydrochloride. In chronic dog studies, ophthalmology, hematology, blood chemistry and organ weight parameters were unaffected by olopatadine hydrochloride administration.

A one-month topical ocular study was conducted with 0.1% QID or 0.2% olopatadine hydrochloride QID and HID ophthalmic solution in New Zealand White (NZW) rabbits. No signs of pharmacotoxicity were observed. Slit-lamp and indirect ocular evaluations and pachymetry revealed no treatment-related findings. Clinical pathology data and histopathology were unremarkable.

Two one-day topical ocular studies were conducted in NZW rabbits with 0.2% olopatadine hydrochloride formulations containing povidone. Each animal received two drops of the test article to one eye every 30 minutes for a total of ten doses. Slit lamp biomicroscopic examinations were conducted at 1, 2, 3 days following treatment. No significant ocular irritation was observed.

Reproductive and Developmental Toxicology:

Chronic topical ocular studies were conducted with olopatadine hydrochloride in rabbits and monkeys. Administration of olopatadine hydrochloride at concentrations of 0.1, 0.5 and 1.0% QID to NZW rabbits elicited no signs of pharmacotoxicity. No treatment-related findings were observed during slit-lamp and indirect ocular evaluations and pachymetry measurements. Clinical pathology data and histopathology were unremarkable. Similar findings were observed following six months of topical ocular administration of olopatadine hydrochloride at concentrations of 0.1, 0.2 and 0.5% QID to cynomolgus monkeys and following three months of topical ocular administration of formulations containing 0.2 and 0.4% of olopatadine hydrochloride with povidone TID to rabbits.

Juvenile Toxicity:

Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 150,000 times the MROHD and rabbits treated at 400 mg/kg/day, or approximately 100,000 times the MROHD, during organogenesis showed a decrease in live fetuses. In addition, rats treated with 600 mg/kg/day of olopatadine during organogenesis showed a decrease in fetal weight. Further, rats treated with 600 mg/kg/day of olopatadine during late gestation through the lactation period showed a decrease in neonatal survival and body weight.

Special Toxicology:

Antigenicity: Olopatadine hydrochloride was demonstrated to have a low potential for antigenicity when tested in mice and guinea pigs or in an *in vitro* passive hemagglutination test. Olopatadine was tested in a series of *in vitro* and *in vivo* mutagenesis studies. The results of these studies demonstrated that treatment with olopatadine did not induce genetic mutations or chromosomal aberrations. Long-term carcinogenicity studies in rats and mice also demonstrated that treatment with olopatadine did not increase the potential for cancer up to 500 mg/kg/day or over 200,000 fold greater than the maximum recommended daily dose.

17 SUPPORTING PRODUCT MONOGRAPHS

^{Pr}PATADAY® (Ophthalmic Solution, 0.2% w/v), submission control 266071, Product Monograph, Novartis Pharmaceuticals Canada Inc. (June 23, 2023)

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr **AG-Olopatadine 0.2%**

Olopatadine Hydrochloride Ophthalmic Solution

Read this carefully before you start taking **AG-Olopatadine 0.2%** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **AG-Olopatadine 0.2%**.

What is AG-Olopatadine 0.2% used for?

AG-Olopatadine 0.2% is used for the treatment of itchy eyes caused by seasonal allergies.

How does AG-Olopatadine 0.2% work?

Itchy eyes due to seasonal allergies, also called allergic conjunctivitis, happens when allergens like pollen cause the cells of the eye to release a chemical called histamine. This can result in itching, redness and swelling on the surface of your eye. AG-Olopatadine 0.2% works by stopping the release of histamine and other chemicals that cause the allergic reaction. This reduces eye itching.

What are the ingredients in AG-Olopatadine 0.2%?

Medicinal ingredient: Olopatadine hydrochloride

Non-medicinal ingredients: Benzalkonium chloride (preservative), dibasic sodium phosphate, edetate disodium, hydrochloric acid and / or sodium hydroxide (to adjust pH), povidone, sodium chloride, water for injection.

AG-Olopatadine 0.2% comes in the following dosage forms:

Ophthalmic solution (eye drops); 0.2% w / v olopatadine (as olopatadine hydrochloride)

Do not use AG-Olopatadine 0.2% if:

- you are allergic to olopatadine hydrochloride or to any of the other ingredients (see **What are the ingredients in AG-Olopatadine 0.2%?**).

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take AG-Olopatadine 0.2%. Talk about any health conditions or problems you may have, including if you:

- are pregnant or planning to become pregnant.
- are breastfeeding. AG-Olopatadine 0.2% may pass into breastmilk.
- are under 18 years of age.

Other warnings you should know about:

• **Use of AG-Olopatadine 0.2% and use of contact lenses:**

- Do not wear contact lenses if your eyes are red.
- AG-Olopatadine 0.2% contains a preservative, benzalkonium chloride, which may cause eye irritation and is known to discolour soft contact lenses. Do not use AG-Olopatadine 0.2% while wearing contact lenses.
- Remove your contacts before using AG-Olopatadine 0.2% and wait at least 15 minutes before putting your contacts back in.

• **Use of AG-Olopatadine 0.2% with other eye drops or ointments:**

- If you use other eye drops, wait at least 5 minutes between putting in AG-Olopatadine 0.2% and the other drops.
- Apply eye ointments last.

- **Driving and using machines:** You may find that your vision is blurred for a time just after you use AG-Olopatadine 0.2%. Do not drive or use machines until your vision is clear.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with AG-Olopatadine 0.2%:

There are no known drugs that interact with AG-Olopatadine 0.2%.

How to take AG-Olopatadine 0.2%:

- AG-Olopatadine 0.2% is an eye drop. Only use it in your eye(s).
- Use AG-Olopatadine 0.2% exactly how your healthcare professional has told you to. Do not change your dose without talking to your healthcare professional.

Usual dose:

Adults: 1 drop in each affected eye once daily.




Figure 1




Figure 2

Instructions for use:

1. Get the AG-Olopatadine 0.2% bottle and a mirror if needed.
2. Wash your hands.
3. Twist off the cap, being careful not to touch the dropper tip.
4. Hold the bottle, pointing it down, between your thumb and

middle finger.

5. Tilt your head back. Pull down your eyelid with a clean finger, until there is a 'pocket' between the eyelid and your eye. The drop will go in there (Figure 1).
6. Bring the bottle tip close to the eye. Use the mirror if it helps.
Do not touch your eye or eyelid, or any surface with the dropper. It could contaminate the drops, cause an eye infection and damage the eyes.
7. Gently press the bottom of the bottle with your forefinger to release one drop (Figure 2). Do not squeeze the bottle: it is designed so that just a gentle press on the bottom is all that it needs.
8. If you use drops in both eyes, repeat the steps for the other eye.
9. Put the bottle cap firmly back on immediately after use.

Overdose:

If you get too much in your eyes, rinse it all out with warm water. Don't put in any more drops until it's time for your next regular dose.

If you think you, or a person you are caring for, have taken too much AG-Olopatadine 0.2%, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed Dose:

If you forget to use AG-Olopatadine 0.2%, use a single drop as soon as you remember, and then go back to your regular routine. **Do not** use a double dose to make up for the one missed.

What are possible side effects from using AG-Olopatadine 0.2%?

These are not all the possible side effects you may have when using AG-Olopatadine 0.2%. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

In the eye:

- eye problems such as dry, itchy, red, irritated or crusted eyes
- eye surface inflammation with or without surface damage
- eye discharge
- eye pain
- increased tear production
- eyelid redness, swelling
- sensitivity to light
- blurred vision
- burning, stinging or gritty feeling or a feeling as if something is trapped in the eye

Other areas of your body:

- headache
- dizziness
- fatigue or tiredness
- nasal dryness
- dry mouth
- change in your sense of taste
- nausea
- red or itchy skin

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
RARE			
Allergic reactions: swelling of the face, lips, tongue, mouth or throat, shortness of breath, difficulty swallowing, hives, severe itching and rash, nausea, vomiting			✓
Increased heart rate		✓	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

- Store between 4-25°C.
- Throw away the bottle at the end of your treatment or 4 weeks after first opening, whichever comes first.

- Do not use if seal is damaged or missing.
- Keep out of reach and sight of children.

If you want more information about AG-Olopatadine 0.2%:

- Talk to your healthcare professional
- Find the full Product Monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); or by calling 450-449-9272.

This leaflet was prepared by:

Angita Pharma Inc.

1310 rue Nobel

Boucherville, Québec

J4B 5H3, Canada

Last Revised: JAN 16, 2026